Leo Lens Pharma (formerly DBA as Leo Lens Technology Co., Inc.) has announced it received a notice of allowance from the USPTO for a patent for the use of its proprietary MediPrint™ process to manufacture a contact lens capable of providing enhanced myopia management.
The novel product will allow patients suffering from, or at a high risk of developing, myopia to wear a contact lens that can automatically and continuously deliver a drug to control myopia, such as low dose Atropine, to the patient’s eye. The MediPrint™ process is compatible with a variety of base contact lenses, allowing Leo Lens Pharma to pair its drug delivery technology with contact lenses designed to help slow the progression of myopia.
The use of contact lens in myopia management is not new. As the stigma of wearing glasses or spectacles leads children with myopia to look for alternatives, contact lens manufacturers have developed lenses to help slow the progression of myopia. Leo Lens Pharma aims to be the first company to pair contact lenses with the continuous delivery of drugs shown to help with myopia management.
“Myopia is a growing epidemic affecting over 2.5B people globally and we are excited to be working on a solution that could have a beneficial impact to a growing number of young patients with myopia globally,” said Praful Doshi, Founder and CTO. “Fortunately, this patent and development effort will benefit from the learnings out of our more immediate focus to help protect sight in the glaucoma market with a weekly continuous dosing therapy made possible by our unique MediPrint™ process.”
While this new patent expands Leo Lens Pharma’s IP portfolio, the Company’s lead proprietary asset is a lens to treat glaucoma. This lens is manufactured with the MediPrint™ process, which allows for the continuous release of FDA approved Bimatoprost. Considering the millions of glaucoma patients diagnosed and treated in the U.S. alone, and the countless others who are undiagnosed or untreated currently, the advent of Leo Lens Pharma’s complete solution for glaucoma treatment will benefit patients and eye care professionals alike. Leo Lens Pharma has already had a successful pre-IND meeting with the FDA to confirm its regulatory strategy and will soon be submitting an IND for a Phase 2a clinical trial with the glaucoma product.